Status:
RECRUITING
AI-assisted Migraine Education: Efficacy, Safety and Patients' Acceptance
Lead Sponsor:
Ente Ospedaliero Cantonale, Bellinzona
Conditions:
Migraine
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Migraine affects 1 in 7 people globally, significantly impacting quality of life and economic productivity. Despite its prevalence, limited awareness leads to misdiagnosis, inadequate treatment, and s...
Detailed Description
Migraine affecting approximately 1 in 7 individuals globally, significantly impacts quality of life and economic productivity due to its associated healthcare and social burdens. Despite its prevalenc...
Eligibility Criteria
Inclusion
- aged between 18 and 65 years at the time of signing the informed consent
- Newly diagnosis of migraine, confirmed through the medical chart
- The participant must be capable of giving signed informed consent
- Access to a laptop, computer, smartphone, or tablet
Exclusion
- Insufficient knowledge of the protocol language (italian)
- Patients with cognitive impairment and/or unable to use or access the AI-powered learning platform developed in this study.
- Vulnerable participants (e.g. minors, participants incapable of judgment or participants under tutelage)
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2026
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT06507150
Start Date
September 1 2024
End Date
August 31 2026
Last Update
February 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ente Ospedaliero Cantonale - Ospedale Regionale di Lugano
Lugano, Switzerland